Cancer Family
Malignant Endocrine Neoplasm
CI-CAN-00000230Explore in graph →
577 active trials16 approved drugs58 evidence items
- NCIt
- C3575
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000230Explore in graph →
Clinical trials
1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (238)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04878016 | A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC | completed | Phase 3 | 498 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03297788 | Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases(ENCEPHALON) | completed | N/A | 56 | Juergen DebusOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04361825 | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects(SUKSES-N4) | completed | Phase 2 | 42 | Se-Hoon LeeOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 24 | Shadia Jalal, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02318784 | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05422781 | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | completed | Phase 1 | 6 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04229381 | Resiliency Among Older Adults Receiving Lung Cancer Treatment(ROAR-LCT) | completed | N/A | 18 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | completed | Phase 1 | 105 | Syros PharmaceuticalsINDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT01401907 | Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | completed | N/A | 351 | Massachusetts General HospitalOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067594 | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | completed | — | 155 | Austral University, ArgentinaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068101 | Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | completed | — | 274 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT00856037 | Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 22 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01659385 | Leptin Levels in Papillary Thyroid Cancer(LL-PTC) | completed | — | 18 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03216343 | Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer | completed | Phase 1 | 48 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT05026593 | A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 60 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02267603 | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05873283 | Papillary Thyroid Cancer and Central Lymp Node Dissection | completed | — | 250 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 1 | May 24, 2023 | clinicaltrials |
| NCT04452292 | Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma(PRECISION-NEC) | completed | N/A | 2 | Charles KunosOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT01440816 | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer(MCC) | completed | Phase 2 | 15 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05344027 | The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma(MitoS-FP) | completed | — | 35 | King's College Hospital NHS TrustOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04672928 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | completed | Phase 1 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05673798 | Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients | completed | — | 569 | The Second Hospital of Shandong UniversityOTHER | 0 | Jan 10, 2023 | clinicaltrials |
| NCT05285033 | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC(LURBICLIN) | completed | — | 312 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05671393 | the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma | completed | — | 801 | Fujian Medical UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03545334 | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study(LIMIT) | completed | N/A | 93 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT03079440 | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01013779 | Merkel Positron Emission Tomography (PET) Protocol(MP3) | completed | Phase 2 | 43 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT04478175 | Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology(DParcoursDig) | completed | N/A | 30 | Institut CurieOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT00540566 | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | completed | — | 113 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT01860898 | A Phase I Study of iPS Cell Generation From Patients With COPD | completed | N/A | 31 | Mayo ClinicOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04483349 | Assessment of What Patients and Healthcare Providers Value | completed | — | 397 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03232593 | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | completed | — | 1,758 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02205515 | An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis(EBRT) | completed | Phase 1 / Phase 2 | 17 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 2, 2024source: clinicaltrials